Ensysce Biosciences, Inc. (ENSC) Form 10-Q — May 15, 2026
Ensysce Biosciences reported a net loss of $3.6 million for the first quarter of 2026, driven by a $3.3 million increase in R&D expenses related to its Phase 3 PF614 clinical trial. The company generated only $961,000 in revenue from federal grants, resulting in a cash balance of just $745,000 as of March 31, 2026. The filing includes explicit going-concern language, stating that existing cash resources are sufficient to fund operations only through the late second quarter of 2026. Management acknowledges substantial doubt about the company's ability to continue as a going concern without raising additional capital.
Key figures
- Revenue
- 960999
- Total Debt
- 245849
- Total Assets
- 2167803
- Cash Position
- 745482
- Shares Outstanding
- 9277819
- Ga Expense
- 1176348
- Rd Expense
- 3346881
- Grant Revenue
- 960999
- Operating Loss
- 3562230
- Outstanding Warrants
- 3266088
- Remaining Grant Funding
- 6000000
- Series BPreferred Stated Value
- 1545500
Price after filing
Close on the filing date to close N calendar days later (from $0.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.